Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation
Go back to Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation| Halozyme Therapeutics, Inc. (NASDAQ: HALO) | Delayed: 81.57 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $81.57 | 52 Week High | $18.39 | |||
| Open | $81.57 | 52 Week Low | $6.96 | |||
| Day High | $81.57 | P/E | N/A | |||
| Day Low | $81.57 | EPS | $-0.58 | |||
| Volume | 3,363 | |||||
